Aviir company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

aviir.com

Executives

6

Board of Directors

4

Aviir Board of Directors

4 Board of directors

Aviir has 4 board of directors, including David Rubin.

Name

Firm

Work History

Other Seats

David Rubin

Experienced executive, scientist, investor, and board director with demonstrated leadership history in the biotechnology/pharmaceuticals, diagnostics, device, and healthcare services sectors. R&D and finance professional skilled in company building, Product Management, Board Management, negotiation, compensation/HR, and audit/compliance. Ability to drive actionable innovation in complex business environments. Experience in multiple therapeutic areas including oncology, CNS, cardiovascular, and infectious disease, with strong digital health experience.

Aviir

Paul Klingenstein

Paul Klingenstein founded Aberdare in 1999. His recent focus has been on technologies which drive transformational efficiencies in care, leading Aberdare commitments in areas such as personalized medicine (Clovis Oncology) and biosensor systems and data analytics (mc10, RxAnte). Earlier at Aberdare, he helped establish the firm as a leading healthcare venture investor through commitments to more traditional technologies such as drug discovery and development and highly engineered interventional devices. Prior to founding Aberdare, Paul was an advisor to the Rockefeller Foundation, where he helped launch an early public private partnership (IAVI), directed at finding a broadly effective vaccine for HIV. Earlier in his career he worked at Accel Partners and Warburg Pincus. Paul received his AB in anthropology from Harvard and his MBA from Stanford.

Aviir

Vijay Lathi

Vijay Lathi is a Managing Director focused on information convergence and diagnostics investments. Vijay joined Sprout in 1998, was promoted to Partner in 2003, and was one of the founders of New Leaf in 2005. Prior to focusing on information convergence, Vijay’s investment activity covered a range of healthcare technologies including HCIT, diagnostics and therapeutic platforms, and was the founding investor in both Ilypsa (sold to Amgen) and Relypsa (RLYP). Prior to joining Sprout, Vijay was an analyst in the Healthcare Venture Capital Group at Robertson Stephens & Co. and analyst at Cornerstone Research, a consulting firm focused on financial and economic analysis for business litigation. Vijay graduated from the Massachusetts Institute of Technology and Stanford University where he received his B.S. and M.S. in Chemical Engineering, with an emphasis on the application of engineering to life science technology

Aviir

William Gerber

William Gerber, MD, is an Investment Partner at Bay City Capital and has been with the firm since September 1999. He was most recently President and Chief Executive Officer of Epoch BioSciences, which was acquired by Nanogen in 2004. Prior to joining Epoch, Dr. Gerber served as President and Chief Executive Officer of diaDexus LLC, a joint venture established by Incyte Pharmaceuticals and SmithKline Beecham to apply genomics to the discovery of novel diagnostic products. Dr. Gerber previously served as Vice President and Chief Operating Officer of Onyx Pharmaceuticals, as President of Chiron Diagnostics, and as Senior Vice President and General Manager of the PCR Division of Cetus Corporation. Dr. Gerber is a member of the board of directors of Aviir, Inc., Conatus Pharmaceuticals, Sangamo Biosciences and Vivaldi Biosciences. He also served on and was President of the Board of Medical Quality Assurance, State of California. He received his MD and BS degrees from University of California, San Francisco Medical Center after attending Dartmouth College.

Aviir

Name

David Rubin

Paul Klingenstein

Vijay Lathi

William Gerber

Firm

Work History

Experienced executive, scientist, investor, and board director with demonstrated leadership history in the biotechnology/pharmaceuticals, diagnostics, device, and healthcare services sectors. R&D and finance professional skilled in company building, Product Management, Board Management, negotiation, compensation/HR, and audit/compliance. Ability to drive actionable innovation in complex business environments. Experience in multiple therapeutic areas including oncology, CNS, cardiovascular, and infectious disease, with strong digital health experience.

Paul Klingenstein founded Aberdare in 1999. His recent focus has been on technologies which drive transformational efficiencies in care, leading Aberdare commitments in areas such as personalized medicine (Clovis Oncology) and biosensor systems and data analytics (mc10, RxAnte). Earlier at Aberdare, he helped establish the firm as a leading healthcare venture investor through commitments to more traditional technologies such as drug discovery and development and highly engineered interventional devices. Prior to founding Aberdare, Paul was an advisor to the Rockefeller Foundation, where he helped launch an early public private partnership (IAVI), directed at finding a broadly effective vaccine for HIV. Earlier in his career he worked at Accel Partners and Warburg Pincus. Paul received his AB in anthropology from Harvard and his MBA from Stanford.

Vijay Lathi is a Managing Director focused on information convergence and diagnostics investments. Vijay joined Sprout in 1998, was promoted to Partner in 2003, and was one of the founders of New Leaf in 2005. Prior to focusing on information convergence, Vijay’s investment activity covered a range of healthcare technologies including HCIT, diagnostics and therapeutic platforms, and was the founding investor in both Ilypsa (sold to Amgen) and Relypsa (RLYP). Prior to joining Sprout, Vijay was an analyst in the Healthcare Venture Capital Group at Robertson Stephens & Co. and analyst at Cornerstone Research, a consulting firm focused on financial and economic analysis for business litigation. Vijay graduated from the Massachusetts Institute of Technology and Stanford University where he received his B.S. and M.S. in Chemical Engineering, with an emphasis on the application of engineering to life science technology

William Gerber, MD, is an Investment Partner at Bay City Capital and has been with the firm since September 1999. He was most recently President and Chief Executive Officer of Epoch BioSciences, which was acquired by Nanogen in 2004. Prior to joining Epoch, Dr. Gerber served as President and Chief Executive Officer of diaDexus LLC, a joint venture established by Incyte Pharmaceuticals and SmithKline Beecham to apply genomics to the discovery of novel diagnostic products. Dr. Gerber previously served as Vice President and Chief Operating Officer of Onyx Pharmaceuticals, as President of Chiron Diagnostics, and as Senior Vice President and General Manager of the PCR Division of Cetus Corporation. Dr. Gerber is a member of the board of directors of Aviir, Inc., Conatus Pharmaceuticals, Sangamo Biosciences and Vivaldi Biosciences. He also served on and was President of the Board of Medical Quality Assurance, State of California. He received his MD and BS degrees from University of California, San Francisco Medical Center after attending Dartmouth College.

Other Seats

Aviir

Aviir

Aviir

Aviir

Aviir Management Team

6 Team Members

Aviir has 6 executives. Aviir's former Chief Executive Officer is Rajen K Dalal.

Name

Work History

Title

Status

Rajen K Dalal

Chief Executive Officer

Former

Douglas Harrington

Chief Executive Officer

Former

Maria Messinger

Chief Financial Officer

Former

Bob Harman

Chief Information Officer

Former

Larry Hansen

Chief Commercial Officer

Former

Name

Rajen K Dalal

Douglas Harrington

Maria Messinger

Bob Harman

Larry Hansen

Work History

Title

Chief Executive Officer

Chief Executive Officer

Chief Financial Officer

Chief Information Officer

Chief Commercial Officer

Status

Former

Former

Former

Former

Former

You May Also Like

G
Genera Biosystems

Genera Biosystems is a development phase company that designs, develops and produces and clinically effective human molecular diagnostics with a focus on women's health.

H
Helix Diagnostics

Helix Diagnostics LLC is pursuing development and commercialization of multiplexed DNA detection systems based on capillary electrophoresis.

M
MicroPhage

MicroPhage's mission is to be a worldwide pioneer in rapid bacterial diagnostics, in both bacterial identification and antibiotic susceptibility/resistance testing, through its bacteriophage-based amplification platform for immunoassay diagnostics.

I
Integrative Diagnostics

Integrative Diagnostics is a early cancer detection company founded by Leroy Hood.

3
3PrimiR

3PrimiR is researching how mutations in micro RNA molecules can be used in cancer diagnostics.

C
Columbia BioSystems

Columbia BioSystems Inc. is a company engaged in molecular Nano-diagnostics using Molecularly Imprinted Polymers (MIPs) for the rapid detection of pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA) , Anthrax, HIV, and Trypanosomiasis (sleeping sickness). The company uses MIPs to bind to proteins and, upon binding, change color thereby signaling the presence of the bacteria, virus or parasite.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.